Telix Pharmaceuticals (TLX) Receivables (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Receivables for 3 consecutive years, with $130.5 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables rose 30.08% year-over-year to $130.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $130.5 million (up 30.08% YoY) and the FY2025 annual result came in at $130.5 million, up 29.88% from the prior year.
• Receivables grew to $130.5 million in Q4 2025 per TLX's latest filing, from $100.3 million in the prior quarter.
• Over the last five years, Receivables for TLX reached as high as $130.5 million in Q4 2025 and fell as low as $47.8 million in Q4 2023.
• A 3-year average of $92.9 million and a median of $100.3 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables surged 109.9% — and 2025, when it soared 30.08%.
• Year by year, Receivables stood at $47.8 million in 2023, then jumped by 109.9% to $100.3 million in 2024, then surged by 30.08% to $130.5 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $130.5 million, $100.3 million, and $47.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.